Computational study of inhibitory mechanisms for Janus iron oxide nanoparticles on amyloid aggregations

Abstract

Amyloid aggregation is a ubiquitous form of protein misfolding underlying the pathologies of Alzheimer’s disease (AD), Parkinson’s disease (PD), and type 2 diabetes (T2D), three primary forms of human amyloid diseases. β-casein-coated iron oxide nanoparticles (βCas IONPs) via a BPA-P(OEGA-co-DBM) copolymer linker was recently demonstrated to be a potential universal inhibitor against the amyloidosis of amyloid β (Aβ), α Synuclein (αS) and human islet amyloid polypeptide (IAPP) aggregations in both vitro and vivo.